References
1. Kotseva K., De Backer G, De Bacquer D., et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. Eur. J. Prev. Cardiol. 2021; 28 (4): 370–9.
2. Ference B. A., Ginsberg H.N., Graham I., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2017; 38 (32): 2459–72.
3. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376 (9753): 1670–81.
4. Amarenco P., Kim J.S., Labreuche J., et al. A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020; 382 (1): 9–19.
5. Grundy S.M., Stone N.J., Bailey A.L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019; 73 (24): 3168–209.
6. Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111–88.
7. Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111–88.
8. Ezhov M.V., Sergienko I.V., Aronov D.M., et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision. The Journal of Atherosclerosis and Dyslipidemias. 2017; (3): 5–22. (in Russian)
9. Kukharchuk V.V., Ezhov M.V., Sergienko I.V., et al. Eurasian Association of Cardiology (EAC)/Russian National Atherosclerosis Society (RNAS, Russia) guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian heart journal. 2020; (2): 6–29. (in Russian)
10. Penson P.E., Pirro M., Banach M. LDL-C: lower is better for longer-even at low risk. BMC Med. 2020; 18 (1): 1–6.
11. Rozhkov D.E., Averin E.E., Nikitin A.E., et al. Features of actual state of lipid metabolism in patients after suffering cardiovascular events. Medical alphabet. 2018; 3 (32): 19–28. (in Russian)
12. Banegas J.R., Lopez-Garcia E., Dallongeville J., et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011; 32 (17): 2143–52.
13. Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012; 125 (9): 882–7.
14. Rozhkov D.E., Tyrenko V.V., Nikitin A.E. The problem of achieving the target concentrations of low density lipoproteins cholesterol in real clinical practice: the data of the survey of doctors of different specialties. Therapy 2021; 48 (6): 62–71. (in Russian)